Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7530)
All Articles published online
|
Publishing Process of This Article
|
Jun 7, 2016 (publication date) through Nov 28, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Nakagawa A, Atsukawa M, Tsubota A, Kondo C, Okubo T, Arai T, Itokawa N, Narahara Y, Iwakiri K. Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients. World J Gastroenterol 2016; 22(21): 5104-5113 [PMID: 27275103 DOI: 10.3748/wjg.v22.i21.5104] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i21/5104.htm |
| Number | Citing Articles |
| 1 |
Tomomi Kogiso. Algorithm of ascites management for liver cirrhosis in the tolvaptan era: Paradigm shift treatment improves the outcomes of cirrhotic patients?. Hepatology Research 2023; 53(9): 791 doi: 10.1111/hepr.13941
|
| 2 |
Michitaka Imai, Toru Ishikawa, Yuichi Kojima, Motoi Azumi, Yujiro Nozawa, Tomoe Sano, Akito Iwanaga, Terasu Honma, Toshiaki Yoshida. Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma. European Journal of Gastroenterology & Hepatology 2021; 33(1S): e161 doi: 10.1097/MEG.0000000000001985
|
| 3 |
Masanori Atsukawa, Akihito Tsubota, Koichi Takaguchi, Hidenori Toyoda, Motoh Iwasa, Tadashi Ikegami, Makoto Chuma, Akito Nozaki, Haruki Uojima, Atsushi Hiraoka, Shinya Fukunishi, Keisuke Yokohama, Toshifumi Tada, Keizo Kato, Hiroshi Abe, Joji Tani, Hironao Okubo, Tsunamasa Watanabe, Nobuhiro Hattori, Akemi Tsutsui, Tomonori Senoh, Yuji Yoshida, Tomomi Okubo, Norio Itokawa, Ai Nakagawa‐Iwashita, Chisa Kondo, Taeang Arai, Kojiro Michitaka, Etsuko Iio, Takashi Kumada, Yasushito Tanaka, Yoshiyuki Takei, Katsuhiko Iwakiri. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. Journal of Gastroenterology and Hepatology 2020; 35(7): 1229 doi: 10.1111/jgh.14965
|
| 4 |
Yoshitaka Takuma, Hirokazu Miyatake, Shota Iwadou, Shuji Uematsu, Ryouichi Okamoto, Yasuyuki Araki. Predictive factors for the effectiveness of tolvaptan in liver cirrhosis patients with refractory ascites. Kanzo 2016; 57(12): 684 doi: 10.2957/kanzo.57.684
|
| 5 |
Masato Nakai, Goki Suda, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Ren Yamada, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Naoki Kawagishi, Masatsugu Ohara, Machiko Umemura, Takuya Sho, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto. Durable response without recurrence to Tolvaptan improves long-term survival. Journal of Gastroenterology 2020; 55(12): 1150 doi: 10.1007/s00535-020-01721-8
|
| 6 |
Yoshitaka Arase, Tatehiro Kagawa, Kota Tsuruya, Hirohiko Sato, Erika Teramura, Kazuya Anzai, Shunji Hirose, Ryuzo Deguchi, Koichi Shiraishi, Tetsuya Mine. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites. Clinical Drug Investigation 2019; 39(1): 45 doi: 10.1007/s40261-018-0714-5
|
| 7 |
Takuya Adachi, Akinobu Takaki, Shuichi Sato, Hiroshi Tobita, Haruhiko Kobashi, Masaru Kinomura, Atsuko Nakatsuka, Atsushi Oyama, Nozomu Wada, Masahiro Sakata, Yasuto Takeuchi, Tetsuya Yasunaka, Hideki Onishi, Hidenori Shiraha, Hiroyuki Okada. High expression of a vascular stricture‐related marker is predictive of an early response to tolvaptan, and a low fractional excretion of sodium is predictive of a poor long‐term survival after tolvaptan administration for liver cirrhosis. Hepatology Research 2020; 50(12): 1347 doi: 10.1111/hepr.13573
|
| 8 |
Maiko Namba, Akira Hiramatsu, Hiroshi Aikata, Kenichiro Kodama, Shinsuke Uchikawa, Kazuki Ohya, Kei Morio, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Michio Imamura, Kazuaki Chayama. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. Journal of Gastroenterology 2020; 55(2): 217 doi: 10.1007/s00535-019-01623-4
|
| 9 |
Masayuki Miyazaki, Masayoshi Yada, Kosuke Tanaka, Takeshi Senjyu, Takeshi Goya, Kenta Motomura, Motoyuki Kohjima, Masaki Kato, Akihide Masumoto, Kazuhiro Kotoh. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. World Journal of Gastroenterology 2017; 23(29): 5379-5385 doi: 10.3748/wjg.v23.i29.5379
|
| 10 |
Hiroshi Yoshida, Tetsuya Shimizu, Masato Yoshioka, Nobuhiko Taniai. Management of portal hypertension based on portal hemodynamics. Hepatology Research 2021; 51(3): 251 doi: 10.1111/hepr.13614
|
| 11 |
M. L. Katsin, M. Y. Hurava, Pavel S. Prylutski, A. M. Dzyadz’ko, O. O. Rummo. Pathogenesis and clinical significance of the hyperdynamic circulatory syndrome in liver cirrhosis. Review. Annals of Critical Care 2021; (1): 123 doi: 10.21320/1818-474X-2021-1-123-133
|
| 12 |
Takuya Adachi, Yasuto Takeuchi, Akinobu Takaki, Atsushi Oyama, Nozomu Wada, Hideki Onishi, Hidenori Shiraha, Hiroyuki Okada. Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan. International Journal of Molecular Sciences 2021; 22(11): 5582 doi: 10.3390/ijms22115582
|
| 13 |
Ioannis Bellos, Konstantinos Kontzoglou, Despina N Perrea. Predictors of tolvaptan short‐term response in patients with refractory ascites: A meta‐analysis. Journal of Gastroenterology and Hepatology 2020; 35(2): 182 doi: 10.1111/jgh.14784
|
| 14 |
Jieting Tang, Yongfeng Wang, Tao Han, Qing Mao, Jun Cheng, Huiguo Ding, Jia Shang, Qin Zhang, Junqi Niu, Feng Ji, Chengwei Chen, Jidong Jia, Xiangjun Jiang, Nonghua Lv, Yueqiu Gao, Zhenghua Wang, Zhong Wei, Yingxuan Chen, Minde Zeng, Yimin Mao. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial. BMC Gastroenterology 2020; 20(1) doi: 10.1186/s12876-020-01536-0
|
| 15 |
Masanori Atsukawa, Akihito Tsubota, Keizo Kato, Hiroshi Abe, Noritomo Shimada, Toru Asano, Tadashi Ikegami, Mai Koeda, Tomomi Okubo, Taeang Arai, Ai Nakagawa‐Iwashita, Yuji Yoshida, Korenobu Hayama, Norio Itokawa, Chisa Kondo, Yoshimichi Chuganji, Yasushi Matsuzaki, Katsuhiko Iwakiri. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema. Journal of Gastroenterology and Hepatology 2018; 33(6): 1256 doi: 10.1111/jgh.14047
|
| 16 |
Tomomi Kogiso, Takaomi Sagawa, Kazuhisa Kodama, Makiko Taniai, Katsutoshi Tokushige. Impact of continued administration of tolvaptan on cirrhotic patients with ascites. BMC Pharmacology and Toxicology 2018; 19(1) doi: 10.1186/s40360-018-0277-3
|
| 17 |
Masashi Hirooka, Yohei Koizumi, Ryo Yano, Yoshiko Nakamura, Koutarou Sunago, Atsushi Yukimoto, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Masanori Abe, Yoichi Hiasa. Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-11889-z
|